These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 37077103)

  • 21. Trisomy 5 in Ph+ chronic myeloid leukemia in association with megakaryocytosis.
    Ansell SM; Rapoport BL; Coccia-Portugal MA; Stevens K; Bester CJ; Falkson G
    Cancer Genet Cytogenet; 1991 Feb; 51(2):273-5. PubMed ID: 1993312
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fluorescence in-situ hybridization (FISH) reveals that in chronic myelogenous leukaemia (CML) following interferon-alpha therapy, normalization of megakaryocyte size is associated with the loss of bcr/abl translocation.
    Thiele J; Schmitz B; Gross H; Kvasnicka HM; Niederle N; Leder LD; Fischer R
    Histopathology; 1997 Sep; 31(3):215-21. PubMed ID: 9354890
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inducible expression of BCR/ABL using human CD34 regulatory elements results in a megakaryocytic myeloproliferative syndrome.
    Huettner CS; Koschmieder S; Iwasaki H; Iwasaki-Arai J; Radomska HS; Akashi K; Tenen DG
    Blood; 2003 Nov; 102(9):3363-70. PubMed ID: 12855552
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.
    Bhatia R; Holtz M; Niu N; Gray R; Snyder DS; Sawyers CL; Arber DA; Slovak ML; Forman SJ
    Blood; 2003 Jun; 101(12):4701-7. PubMed ID: 12576334
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BCR/ABL- CD34(+)HLA-DR- progenitor cells in early chronic phase, but not in more advanced phases, of chronic myelogenous leukemia are polyclonal.
    Delforge M; Boogaerts MA; McGlave PB; Verfaillie CM
    Blood; 1999 Jan; 93(1):284-92. PubMed ID: 9864172
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The BCR/ABL transgene causes abnormal NK cell differentiation and can be found in circulating NK cells of advanced phase chronic myelogenous leukemia patients.
    Nakajima H; Zhao R; Lund TC; Ward J; Dolan M; Hirsch B; Miller JS
    J Immunol; 2002 Jan; 168(2):643-50. PubMed ID: 11777957
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Megakaryocyte features and bcr/abl translocation in chronic myeloid leukemia following imatinib mesylate (STI571) therapy--a fluorescence in-situ hybridization study.
    Thiele J; Kvasnicka HM; Varus E; Ollig E; Schmitt-Graeff A; Staib P; Griesshammer M
    Leuk Lymphoma; 2004 Aug; 45(8):1627-31. PubMed ID: 15370216
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy.
    Defina M; Ippoliti M; Gozzetti A; Abruzzese E; Castagnetti F; Crupi R; Tiribelli M; Breccia M; Salvucci M; Aprile L; Baratè C; Gozzini A; Rosti G; Lauria F; Bocchia M
    Cancer; 2012 Nov; 118(21):5265-9. PubMed ID: 22517301
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Megakaryocytic blast crisis as a presenting manifestation of chronic myeloid leukemia.
    Pullarkat ST; Vardiman JW; Slovak ML; Rao DS; Rao NP; Bedell V; Said JW
    Leuk Res; 2008 Nov; 32(11):1770-5. PubMed ID: 18417213
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comparison of the effect of bcr/abl breakpoint specific phosphothiorate oligodeoxynucleotides on colony formation by bcr/abl positive and negative, CD34 enriched mononuclear cell populations.
    Chasty R; Whetton A; Lucas G
    Leuk Res; 1996 May; 20(5):391-5. PubMed ID: 8683978
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Regression of the Philadelphia chromosome (bcr/abl)-positive myelo- and megakaryopoiesis after Imatinib (STI571) therapy in chronic myelogenous leukemia (CML)].
    Thiele J; Kvasnicka HM; Varus E; Kriener S; Engels K; Staib P; Ollig ES; Griesshammer M; Waller CF; Pfeifer H; Schmitt-Gräff A
    Pathologe; 2004 Nov; 25(6):428-35. PubMed ID: 15179523
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib.
    Lemoli RM; Salvestrini V; Bianchi E; Bertolini F; Fogli M; Amabile M; Tafuri A; Salati S; Zini R; Testoni N; Rabascio C; Rossi L; Martin-Padura I; Castagnetti F; Marighetti P; Martinelli G; Baccarani M; Ferrari S; Manfredini R
    Blood; 2009 Dec; 114(25):5191-200. PubMed ID: 19855080
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Megakaryopoiesis and myelofibrosis in chronic myeloid leukemia after allogeneic bone marrow transplantation: an immunohistochemical study of 127 patients.
    Thiele J; Kvasnicka HM; Beelen DW; Flucke U; Spoer C; Paperno S; Leder LD; Schaefer UW
    Mod Pathol; 2001 Feb; 14(2):129-38. PubMed ID: 11235904
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enrichment of normal progenitors in counter-flow centrifugal elutriation (CCE) fractions of fresh chronic myeloid leukemia leukapheresis products.
    Dlubek D; Dybko J; Wysoczanska B; Laba A; Klimczak A; Kryczek I; Konopka L; Lange A
    Eur J Haematol; 2002 May; 68(5):281-8. PubMed ID: 12144534
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression differences of genes in the PI3K/AKT, WNT/b-catenin, SHH, NOTCH and MAPK signaling pathways in CD34+ hematopoietic cells obtained from chronic phase patients with chronic myeloid leukemia and from healthy controls.
    de Cássia Viu Carrara R; Fontes AM; Abraham KJ; Orellana MD; Haddad SK; Palma PVB; Panepucci RA; Zago MA; Covas DT
    Clin Transl Oncol; 2018 Apr; 20(4):542-549. PubMed ID: 28905209
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Philadelphia negative BCR-ABL positive chronic myeloid leukemia mimicking juvenile chronic myeloid leukemia in a 2-year-old child.
    Mahon FX; Labouyrie E; Aurich-Costa J; Dastugue N; Micheau M; Bady C; Perel Y; Bilhou-Nabera C; Reiffers J; Bernard P
    Leuk Lymphoma; 1997 Aug; 26(5-6):615-9. PubMed ID: 9389369
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oncogenic heterogeneous nuclear ribonucleoprotein D-like modulates the growth and imatinib response of human chronic myeloid leukemia CD34
    Ji D; Zhang P; Ma W; Fei Y; Xue W; Wang Y; Zhang X; Zhou H; Zhao Y
    Oncogene; 2020 Jan; 39(2):443-453. PubMed ID: 31488872
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicity.
    Härtel N; Klag T; Hanfstein B; Mueller MC; Schenk T; Erben P; Hochhaus A; La Rosée P
    J Cancer Res Clin Oncol; 2012 Feb; 138(2):203-12. PubMed ID: 22089930
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells.
    Carter BZ; Mak PY; Mak DH; Ruvolo VR; Schober W; McQueen T; Cortes J; Kantarjian HM; Champlin RE; Konopleva M; Andreeff M
    Oncotarget; 2015 Oct; 6(31):30487-99. PubMed ID: 26431162
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thrombopoietin enhances the production of myeloid cells, but not megakaryocytes, in juvenile chronic myelogenous leukemia.
    Sawai N; Koike K; Higuchi T; Ogami K; Oda M
    Blood; 1998 Jun; 91(11):4065-73. PubMed ID: 9596651
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.